Sivaraj, D., Green, M. M., Kang, Y., Long, G. D., Rizzieri, D. A., Li, Z., … Gasparetto, C. (2018). Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood Cancer J, 8(8), 71. https://doi.org/10.1038/s41408-018-0104-5

Sivaraj, Dharshan, Michael M. Green, Yubin Kang, Gwynn D. Long, David A. Rizzieri, Zhiguo Li, Anderson H. Garrett, Jackie L. McIntyre, Nelson J. Chao, and Cristina Gasparetto. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.” Blood Cancer J 8, no. 8 (July 31, 2018): 71. https://doi.org/10.1038/s41408-018-0104-5.

Sivaraj D, Green MM, Kang Y, Long GD, Rizzieri DA, Li Z, et al. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood Cancer J. 2018 Jul 31;8(8):71.

Sivaraj, Dharshan, et al. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.” Blood Cancer J, vol. 8, no. 8, July 2018, p. 71. Pubmed, doi:10.1038/s41408-018-0104-5.

Sivaraj D, Green MM, Kang Y, Long GD, Rizzieri DA, Li Z, Garrett AH, McIntyre JL, Chao NJ, Gasparetto C. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood Cancer J. 2018 Jul 31;8(8):71.